Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML. - Wikidata - awgldk - TriplyDB

Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.

Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.

http://www.wikidata.org/entity/Q35164242

about

Implications of Genetic and Epigenetic Alterations of CDKN2A (p16(INK4a)) in Cancer Confirmatory Trials in the Evaluation of Anticancer Medicinal Products in Man--PFS2: A Measure of Therapeutic Action-At-A-Distance Concise review: Leukemia stem cells in personalized medicine Therapeutic Resistance in Acute Myeloid Leukemia: The Role of Non-Coding RNAs Epigenetics in Brain Tumors: HDACs Take Center Stage Sequential treatment with cytarabine and decitabine has an increased anti-leukemia effect compared to cytarabine alone in xenograft models of childhood acute myeloid leukemia.The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.Sequential combination of decitabine and idarubicin synergistically enhances anti-leukemia effect followed by demethylating Wnt pathway inhibitor promoters and downregulating Wnt pathway nuclear target.Epigenetic therapies in MDS and AML Epigenetics in clinical practice: the examples of azacitidine and decitabine in myelodysplasia and acute myeloid leukemia.Epigenetic signaling in schizophrenia Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.Augmenting antitumor immune responses with epigenetic modifying agents.Efficacy and safety of decitabine in combination with G-CSF, low-dose cytarabine and aclarubicin in newly diagnosed elderly patients with acute myeloid leukemia What is memory? The present state of the engram.Autoimmune disease in the epigenetic era: how has epigenetics changed our understanding of disease and how can we expect the field to evolve?Antineoplastic activity of the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine in anaplastic large cell lymphoma.Epigenetics as a therapeutic target in breast cancer.The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients.A Study of Human Leukocyte Antigen Mismatched Cellular Therapy (Stem Cell Microtransplantation) in High-Risk Myelodysplastic Syndrome or Transformed Acute Myelogenous Leukemia.Hypomethylation of TET2 Target Genes Identifies a Curable Subset of Acute Myeloid Leukemia.Strategies to reduce relapse after allogeneic hematopoietic cell transplantation in acute myeloid leukemia.Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone How to manage high-risk acute myeloid leukemia.Acute myeloid leukemia: focus on novel therapeutic strategies.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Optimization of cytarabine (ARA-C) therapy for acute myeloid leukemia.Tosedostat for the treatment of relapsed and refractory acute myeloid leukemia.Epigenetics: A primer for clinicians.Preclinical and phase I results of decitabine in combination with midostaurin (PKC412) for newly diagnosed elderly or relapsed/refractory adult patients with acute myeloid leukemia.CEBPA-CEBPG axis as a novel promising therapeutic target in acute myeloid leukemia.Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis.Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.Phase I Study of Epigenetic Priming with Azacitidine Prior to Standard Neoadjuvant Chemotherapy for Patients with Resectable Gastric and Esophageal Adenocarcinoma: Evidence of Tumor Hypomethylation as an Indicator of Major Histopathologic Response.Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.A multicenter, randomized study of decitabine as epigenetic priming with induction chemotherapy in children with AML.GADD45A methylation predicts poor overall survival in acute myeloid leukemia and is associated with IDH1/2 and DNMT3A mutations.Entinostat prevents leukemia maintenance in a collaborating oncogene-dependent model of cytogenetically normal acute myeloid leukemia.D-CAG (decitabine followed by cytarabine, aclarubicin, and G-CSF) for relapsed acute myeloid leukemia after hematopoietic cell transplantation.A novel regimen for relapsed/refractory adult acute myeloid leukemia using a KMT2A partial tandem duplication targeted therapy: results of phase 1 study NCI 8485.

P2860

Q26739706-08EC7F22-5166-421D-8B19-A457EF0EAA56 Q26782138-F26B359C-C4EA-4E6B-80C5-71AFDADF7916 Q26995268-494D0A1D-7681-4B7A-9344-2A5EFE8789A4 Q28071427-A14567C5-17BE-46AA-8965-8424B02739C4 Q28080964-494A83CA-6DD7-4729-875E-E927F075AA06 Q31149399-8020AC02-880C-4392-981E-FBCD7CC95DF9 Q33578787-CE9B9429-4A72-4093-BA40-61A50706D9DB Q33847891-06DBB954-9B3F-4ACF-850A-4A9733D324F4 Q33863567-1939DE78-2EAA-40B0-A08D-7EAC9EDF2F21 Q34350209-88506EAC-59AD-4121-B06A-B7BF16E1168B Q34482708-5E308719-554D-46AA-931C-BAE5CB776F06 Q34541052-683BC44E-EA7B-4914-AFFF-5F0C52EFC8F8 Q35048054-62AD39B5-5C0C-4113-AC31-AA7F6FE34D5E Q35742564-CD937C40-2E9C-4B84-8EF6-7B33C65EA847 Q36022984-FB078060-E463-4A27-96D4-2ACC9A952C44 Q36257320-73E24626-D8F2-440F-B1C8-21B91079BF64 Q36345656-2D04A3AD-94D8-4D1E-8E66-007573DD8448 Q36449057-94DF79D1-8F64-4085-AD02-8F6150EA176C Q36545229-88FC4723-2F84-4A81-8511-BDABF64C0EA3 Q36703031-77A56176-4D23-470C-B605-38AA60AD9661 Q36887700-467E289E-1174-43BA-9BC9-03837907C8AE Q37000485-233FDB9F-8A29-4CE4-88EB-B0C5939770F6 Q37742267-F36D00D0-0F7E-47E2-88B2-928704FD190D Q37960820-E7821EF8-46BD-4481-83BC-DF1F0EA0F4F0 Q38015336-EDB32BB2-2D0C-429B-912B-D4A7AA250687 Q38097334-559A18FC-EC70-4FD2-BD24-37E871C63E3F Q38126936-B10ED737-340A-4E85-9075-D35F834069C4 Q38169200-451256EB-018D-4505-B050-FC10B0DDFFDC Q38770916-1E35ED32-90AB-4372-BBE9-FB11FC924793 Q39135512-08104976-6407-4C2F-91F4-1E648036A766 Q39286221-D35FB597-FF21-49F5-96B1-C47FB176FC41 Q39295844-859EB0CB-E4D9-47EC-8446-2360283952BA Q40055082-E9824A6A-ACE1-434B-AFC9-397FFC14665A Q40419898-F8CA5DCE-9F01-4C0A-A7B8-BB75A91A0543 Q41161466-FAAB1B56-2DFA-4720-B692-877F8B46F86C Q42371209-0133E3E7-F5AE-432E-B156-E067D5B64F1E Q43674178-BFAAF2C5-9AA6-47D5-8DC9-B2F36573B8A1 Q45754556-6BD71B8B-9BF0-48D7-BD0F-76AC5D976F23 Q51594039-0A97EC66-C1B0-4237-9509-6F483D5F1B5E Q52641884-11DCF28E-D033-4E74-92DB-2DFAF702D8FE

P2860

Phase 1 study of epigenetic priming with decitabine prior to standard induction chemotherapy for patients with AML.

http://www.wikidata.org/entity/Q35164242

description

2011 nî lūn-bûn

@nan

2011 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Phase 1 study of epigenetic pr ...... therapy for patients with AML.

@ast

Phase 1 study of epigenetic pr ...... therapy for patients with AML.

@en

type

label

Phase 1 study of epigenetic pr ...... therapy for patients with AML.

@ast

Phase 1 study of epigenetic pr ...... therapy for patients with AML.

@en

prefLabel

Phase 1 study of epigenetic pr ...... therapy for patients with AML.

@ast

Phase 1 study of epigenetic pr ...... therapy for patients with AML.

@en

P1433

Q35164242-6A242C2D-BD36-4319-AA0D-09C4A44BFDA0

P1476

Q35164242-F71B02A1-29B1-41C3-A248-9647367A8C0C

P2093

Q35164242-0B82993C-5EFF-4F40-8F60-78E43110E445

Q35164242-35C829C3-3D60-4A6B-9BF2-B92A45A992DB

Q35164242-45C0C1BE-0E23-4838-8298-27E216F621B9

Q35164242-5667CB9F-D8B4-43E0-A985-3E9FADC27208

Q35164242-64E1520E-685F-4817-B2FD-299C2BB89B2A

Q35164242-71F0D327-1546-483A-BF36-A2FCB335D59D

Q35164242-744E2448-4835-49C4-862F-8916550DDF58

Q35164242-8F80221E-35EE-4F30-A7BA-9A20F507EC2E

Q35164242-9E951F61-465E-4E2A-B1B5-22D506B3849F

Q35164242-AECBC26F-C093-4867-BA19-BF63C333D646

P2860

Q35164242-0191EE7E-523D-4FBF-886A-83576FE6DEE9

Q35164242-06EB4850-5D14-4E55-AF9A-A5D8F91AF9B2

Q35164242-0B1BCFC5-7C59-427E-8577-240EE6265106

Q35164242-12B5A948-23B7-412A-9829-701901C432C1

Q35164242-1A2FC4EB-7B87-405C-8B33-84D8F3D5A027

Q35164242-1EB0EB42-A45E-4DDF-89E8-B68F0045BDED

Q35164242-2DCAE798-C539-4307-869A-A46A81316AE6

Q35164242-406ECC45-FDB9-4FFE-9E21-A25975BCC84D

Q35164242-63A88B3A-C2CE-44A7-831E-EBF3FF0EDBF9

Q35164242-6640B478-A7BF-4576-9EA5-23062A6B204D

P304

Q35164242-DBFDF832-C014-470A-ABE1-CE0AFA4B5571

P31

Q35164242-FB0805F6-74A0-4FBD-A117-F06981205A5B

P356

Q35164242-BA7110AE-6D5E-4B10-9741-57E5A942EDD7

P407

Q35164242-B8EC4FD4-C9CF-4AB2-904D-0E2887449CFC

P433

Q35164242-F717095C-0134-4883-9031-04E140CDC40F

P478

Q35164242-9DEB4CB0-0A43-4C45-99C0-B71C1F59AF67

P50

Q35164242-D3CFC09D-CAAC-40D4-BA17-6C643EB0E7F1

P577

Q35164242-6AF8ABF6-49B0-4E86-B0BC-EDAB5AB796A9

P5875

Q35164242-051586CF-701E-486A-81A7-BD3AF0E201A7

P698

Q35164242-86A15E71-DCC5-4A5E-873A-6E2147389D0B

P921

Q35164242-2FDD7310-313C-4546-AE91-FDFD24514C94

P932

Q35164242-A7DAC0F9-85D8-44E3-91DD-FCD87462B029

P356

BLOOD-2010-11-320093

P1433

P1476

Phase 1 study of epigenetic pr ...... therapy for patients with AML.

@en

P2093

Cindy M Ippoliti

http://www.w3.org/2001/XMLSchema#string

Ellen K Ritchie

http://www.w3.org/2001/XMLSchema#string

Eric J Feldman

http://www.w3.org/2001/XMLSchema#string

Ewelina Morawa

http://www.w3.org/2001/XMLSchema#string

Fabienne Brenet

http://www.w3.org/2001/XMLSchema#string

Gail J Roboz

http://www.w3.org/2001/XMLSchema#string

J Robi Bose

http://www.w3.org/2001/XMLSchema#string

Luis Villegas

http://www.w3.org/2001/XMLSchema#string

Michelle Moh

http://www.w3.org/2001/XMLSchema#string

Sebastian A Mayer

http://www.w3.org/2001/XMLSchema#string

P2860

Analysis of repetitive element DNA methylation by MethyLight.

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties

Sensitization by 5-aza-2'-deoxycytidine of leukaemia cells with MLL abnormalities to induction of differentiation by all-trans retinoic acid and 1alpha,25-dihydroxyvitamin D3.

A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer.

DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes

Epigenetic changes in the myelodysplastic syndrome.

Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine.

Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.

P304

1472-1480

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-11-320093

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

118

http://www.w3.org/2001/XMLSchema#string

P50

Joseph M. Scandura

P577

2011-05-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51165901

http://www.w3.org/2001/XMLSchema#string

P698

21613261

http://www.w3.org/2001/XMLSchema#string

P921

P932

3156041

http://www.w3.org/2001/XMLSchema#string